L&C Bio corrected a material event report in which it set the paid-in capital increase issue price and adjusted the listing schedule.

L&C Bio corrected the material event report (decision on paid-in and free capital increases) disclosed on July 31, 2026. The new share issue price for the paid-in capital increase was finally set at KRW 39,100 (common shares), and the listing dates for the paid-in capital increase and free capital increase were each adjusted by 1 days. The paid-in capital increase will issue 3,700,000 shares (common shares) for purposes including facility funds of KRW 105 billion, operating funds of KRW 24.67 billion, and debt repayment funds of KRW 15 billion.

1. 01

   The paid-in capital increase new share issue price was set at KRW 39,100, a correction following the final determination of the issue price.

2. 02

   The paid-in capital increase listing date was adjusted from November 3, 2026 to November 4, 2026, and the free capital increase listing date was adjusted from November 11, 2026 to November 12, 2026, each by 1 days.

3. 03

   The paid-in capital increase will proceed by way of shareholder allocation followed by public offering of unexercised shares, with 2% allocated to the employee stock association and the remainder allocated to existing shareholders.

4. 04

   The company said the free capital increase will be allocated at a ratio of 1 shares per share, with shareholders recorded in the shareholder register after the paid-in capital increase as the allocation recipients.

An AI model translated the Korean summary of this filing into English; every number is carried over from the Korean original. Reference information, not investment advice.

Key figures

Paid-in capital increase new share issue quantity

3,700,000 shares (common shares)

New share issue price

KRW 39,100 (common shares)

Purpose of fund raising

Facility funds KRW 105 billion, operating funds KRW 24.67 billion, debt repayment funds KRW 15 billion

Paid-in capital increase listing date

November 4, 2026 (before correction: November 3, 2026)

Free capital increase new share issue quantity

30,437,464 shares (common shares)

Free capital increase listing date

November 12, 2026 (before correction: November 11, 2026)

Filing facts

Filing type

Bonus Issue

Report name

[Amended] Decision on Rights Offering and Bonus Issue

Filed

Oct 12, 2026

Receipt number

20261012000188